ArticleJCI insight2020
Immune cell repertoires in breast cancer patients after adjuvant chemotherapy.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.Nature medicine · 2024Trial
- Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.Signal transduction and targeted therapy · 2024Trial
- Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy.Molecular oncology · 2026Article
- Recent advances in understanding chemotherapy-induced fatigue in BC patients residing in high-altitude regions: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Immunological consequences of chemotherapy: implications for cancer immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Circulating T-cell receptor repertoire and clinicopathological correlations in breast cancer patients: immune repertoire analysis from the VGH-TAYLOR study.Breast cancer research : BCR · 2025Article
- Leukocyte Ratios Predict Metastasis, Recurrence, and Mortality in Breast Cancer Patients Receiving Cytotoxic Chemotherapy.Medical sciences (Basel, Switzerland) · 2025Observational
- Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44Journal for immunotherapy of cancer · 2025Article
- Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings.The oncologist · 2025Article
- Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.NPJ breast cancer · 2025Article
- Clinical application of PBMCs in breast cancer: detection, treatment evaluation and prognosis.Frontiers in cell and developmental biology · 2025Review
- Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation.NPJ breast cancer · 2024Article
- Circulating Leukocyte Subsets Before and After a Breast Cancer Diagnosis and Therapy.JAMA network open · 2024Article
- MDR1-EXPRESSING CD4Journal for immunotherapy of cancer · 2023Article
- Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?Current treatment options in oncology · 2023Review
- A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.NPJ breast cancer · 2023Article
- Reactive myelopoiesis and FX-expressing macrophages triggered by chemotherapy promote cancer lung metastasis.JCI insight · 2023Article
- Immunotherapy Approaches for Breast Cancer Patients in 2023.Cold Spring Harbor perspectives in medicine · 2023Review
- Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer.Therapeutic advances in medical oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Adjuvant chemotherapy in breast cancer patients causes immune cell depletion at an age when the regenerative capacity is compromised. Successful regeneration requires the recovery of both quantity and quality of immune cell subsets. Although immune cell numbers rebound within a year after treatment, it is unclear whether overall compositional diversity is recovered. We investigated the regeneration of immune cell complexity by comparing peripheral blood mononuclear cells from breast cancer patients ranging from 1-5 years after chemotherapy with those of age-matched healthy controls using mass cytometry and T cell receptor sequencing. These data reveal universal changes in patients' CD4+ T cells that persisted for years and consisted of expansion of Th17-like CD4 memory populations with incomplete recovery of CD4+ naive T cells. Conversely, CD8+ T cells fully recovered within a year. Mechanisms of T cell regeneration, however, were unbiased, as CD4+ and CD8+ T cell receptor diversity remained high. Likewise, terminal differentiated effector memory cells were not expanded, indicating that regeneration was not driven by recognition of latent viruses. These data suggest that, while CD8+ T cell immunity is successfully regenerated, the CD4 compartment may be irreversibly affected. Moreover, the bias of CD4 memory toward inflammatory effector cells may impact responses to vaccination and infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.